Project Grant R43HL180095
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $448K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Montclair, NJ 07042, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Sigt LLC $848,381 on September 1, 2026, to develop a clinical-grade intraoperative cardiac pulsed field ablation and lesion assessment system under the Cardiovascular Diseases Research program (CFDA 93.837), a Phase II Small Business Innovation Research project. Sigt LLC will develop a pulsed field ablation lesion assessment system (PFA-LAS) using proprietary high frequency dielectric sensing (HFDS) technology to enable intraoperative...
- The National Heart, Lung, and Blood Institute awarded Coridea, LLC $305,365 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cooled radiofrequency bronchoscopic lung volume reduction technology for severe emphysema patients. The project addresses a clinical gap in lung volume reduction therapy. Current surgical options reach only a fraction of severe emphysema patients: wedge excision LVR surgery is invasive and limits candidate eligibility, while...
- The National Heart, Lung, and Blood Institute awarded $598,636 to Spheric Bio Inc. on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop the EMULAATE platform, a patient-specific left atrial appendage occlusion (LAAO) device for stroke prevention in atrial fibrillation patients. Spheric Bio is developing EMULAATE to assemble fully soft, personalized implants directly inside the patient's body through a minimally invasive approach by delivering,...
- The National Heart, Lung, and Blood Institute awarded $293,759 to Coridea, LLC on August 15, 2026, under the Cardiovascular Diseases Research SBIR program (CFDA 93.837) to develop a closed-loop percutaneous stellate ganglion nerve stimulation (SGNS) system for hemodynamic support in septic shock. Coridea will engineer a custom percutaneous neurostimulation lead with imaging-visible electrodes and fixation features to enable stable, reproducible access to the left stellate ganglion during patient...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded Aust Development, LLC a Phase I Small Business Innovation Research project grant of $626,604 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). Aust Development will develop a novel 3D pre-shaped delivery catheter platform to enable precise identification and safe delivery of cardiac conduction system pacing leads. The delivery system will allow physicians to sequentially map the septal myocardium, fix...
- The National Heart, Lung, and Blood Institute awarded Corvion, Inc. $2,999,968 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel pediatric left ventricular assist device (P-LVAD) enabling children with end-stage heart failure to discharge home while awaiting heart transplantation or living long-term with the device. This is a Project Grant (SBIR Phase II). Corvion will engineer an implantable, ultra-low-power blood pump combining hydrodynamic...
- The National Heart, Lung, and Blood Institute awarded Starlight Cardiovascular, Inc. $499,952 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 10, 2026, to advance commercialization of a catheter-delivered, adjustable percutaneous pulmonary flow restrictor designed to replace surgical pulmonary artery banding in newborns with hypoplastic left heart syndrome and other congenital heart defects. The flow restrictor addresses clinical limitations of current surgical...
- Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...
- The National Heart, Lung, and Blood Institute awarded Bridgesource Medical, Corp. $320,727 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a right heart catheter device that uses pressure-volume loop analysis to identify which patients with tricuspid regurgitation will benefit from percutaneous valve repair procedures. The device addresses a critical clinical gap in patient selection for tricuspid valve interventions. Approximately 1.5 million...